

Results of Two Phase 1 Dose Escalation Studies of the Oral Heat Shock Protein 90 (Hsp90) Inhibitor SNX-5422

Todd M. Bauer,¹ Jeffrey R. Infante,¹ Ramesh K. Ramanathan,² Glen J. Weiss,² Jasjit Sachdev,² Howard A. Burris III,¹ James M. Hinson, Jr.,³ Everardus O. Orlemans⁴

¹Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; ²Virginia G. Piper Cancer Center/TGEN, Scottsdale, AZ; ³Unicorn Pharma Consulting, Brentwood, TN; ⁴Esanex, Inc., Indianapolis, IN

BACKGROUND

- Heat shock protein 90 (Hsp90) is a molecular chaperone that is exploited by cancer cells for at least two purposes:
 - To activate and stabilize labile forms of oncoproteins, including many kinases and transcription factors, that have undergone biochemical transformations (mutation, translocation, amplification, overexpression); and
 - To act as a buffer against the cellular stresses essential for cancer cell survival.¹
- Hsp90 inhibition has shown clinical activity in cancers addicted to particular driver oncogenes, such as HER2, EML4-ALK, and mutated EGFR.¹
- SNX-5422 is an orally bioavailable prodrug of SNX-2112, which is a highly potent, non-geldanamycin analog Hsp90 inhibitor.²
- SNX-5422 has extended tumor residence time and has demonstrated significant antitumor activity in multiple mouse xenograft models of human tumors, including lung, breast, and multiple myeloma.^{2,3}
- Two Phase 1 studies have been conducted in patients with refractory solid tumor malignancies or non-Hodgkin's lymphoma (reported here).

OBJECTIVES

- Primary**
 - To evaluate safety of SNX-5422, including determination of dose limiting toxicities (DLTs) and maximum tolerated doses (MTDs).
- Secondary**
 - To characterize the pharmacokinetics (PK) of SNX-5422 and its active metabolite, SNX-2112.
 - To investigate the tumor response to SNX-5422.

METHODS

- Study Design**
 - Two Phase 1, multicenter, open-label, 3+3 dose-escalation studies.
 - SNX-5422-CLN1-001: SNX-5422 administered (a) once daily every day (QD) for 28 out of 28 days, or (b) QD for 21 out of 28 days, followed by 7-day period without study drug, or (c) once daily every other day (QOD) for 21 out of a 28-day cycle, followed by 7-day period without study drug. Dosing schedule:
 - 50 mg/m² QD x 28 days
 - 50 to 89 mg/m² QD x 3 weeks on/1 week off
 - 4 to 100 mg/m² QOD x 3 weeks on/1 week off
 - SNX-5422-CLN1-004: SNX-5422 administered QOD for 21 days out of a 28-day cycle. Dosing schedule:
 - 100 to 133 mg/m² QOD x 3 weeks on/1 week off
 - Actual dose administered was based on body surface area, calculated via actual body weight at start of each cycle; calculated dose then rounded to nearest mg on dosing chart.
 - Concomitant medications were to be taken ≥1 hour before or 2 hours after SNX-5422, except agents with clinically-relevant cytochrome P450 (CYP) 3A4 metabolism that were to be taken at least 3 hours before or 3 hours after SNX-5422.
- No uncontrolled known brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.**
- No anticancer therapy currently or within the 28 days or 5 half-lives (whichever was shorter) before study entry, and all adverse events (AEs) recovered to at least ≤ Grade 1 toxicity level.**
- No gastrointestinal (GI) diseases or conditions (including chronic diarrhea) affecting drug absorption (including gastric bypass) or safety assessments (e.g., Crohn's disease, irritable bowel syndrome).**
- No glaucoma, retinitis pigmentosa, macular degeneration, or any retinal changes detected by ophthalmological examination.**

Safety and Efficacy Analysis

- Adverse event data for the 2 studies were combined.
- Efficacy data from the QOD (3 weeks on/1 week off) population in Study SNX-5422-CLN1-001 was combined with data from Study SNX-5422-CLN1-004; other dosing groups from SNX-5422-CLN1-001 were analyzed separately.
- Tumor response was assessed every 8 weeks using RECIST 1.1 criteria for solid tumors or the Lymphoma Response Criteria for lymphomas (version 1.0). Only patients with post-baseline disease assessment data are included in the tabulation of best response to treatment.

Pharmacokinetic Analysis

- Serial blood samples for the main PK analyses of SNX-5422 and SNX-2112 were collected within 4 hours pre-dose and up to 24-48 hours post-dose on Day 1 and Day 21 of Cycle 1.
- PK parameters calculated using non-compartmental methods; data then summarized.

RESULTS

Table 1. Baseline Characteristics

Parameter	N=56
Age, median (range), years	61 (37-80)
Age >65 years, n (%)	23 (41%)
Males, n (%)	34 (61%)
Race, n (%)	
White	51 (91.1%)
Hispanic or Latino	3 (5.3%)
Black or African-American	2 (3.6%)
Primary Tumor, n (%)	
Prostate	11 (19.6%)
Breast	6 (10.7%)
Colon	6 (10.7%)
Rectal	4 (7.1%)
Lung (NSCLC)	4 (7.1%)
Other*	25 (44.6%)
Prior treatments, n (%)	
Prior systemic therapy (no. regimens)	
0	2 (3.6%)
1-3	17 (30.4%)
>3	37 (66.1%)
Radiotherapy/radiosurgery	20 (35.7%)

* Adrenal gland, anal, bladder, choroidal melanoma, colorectal, endometrial, esophageal, gastrointestinal, GIST, hepatocellular, melanoma, neuroendocrine, pancreas, salivary gland, testicular, thyroid, unknown

Table 2. Dosing Cohorts

Cohort/ Dosing Schedule	Dose (mg/m ²)	Number of Patients Assigned to Cohort	DLT (Cycle 1)
SNX-5422-CLN1-001			
QOD (21/28 days)			
1	4	3	
2	5.32	3	
3	10.64	4	
4	21.28	4	
5	42	4	
6	56	4	
7	100	5	
QD (21/28 days)			
8	50	6	n=1 (diarrhea Grade 3)
9	67	7	n=1 (diarrhea Grade 3)
10	89	3	n=2 (diarrhea Grade 3)
11*	67	1	
QD (28/28 days)			
12	50	3	n=1 (GI hemorrhage Grade 3)
SNX-5422-CLN1-004			
QOD (21/28 days)			
1	133	3	n=2 (diarrhea Grade 3)
2	100	6	

QOD=every other day; QD=once daily. *Patient received 7 doses QD, then switched to QOD schedule during Cycle 1.

Maximum Tolerated Doses

- With the QD dosing regimen, 2 patients on 89 mg/m² experienced DLTs; therefore, the MTD was determined to be 67 mg/m² QD (study SNX-5422-CLN1-001).
- At 133 mg/m² QOD, 2 patients experienced DLTs; therefore, 100 mg/m² QOD was defined as the MTD and that cohort was expanded (study SNX-5422-CLN1-004).

SAFETY

Exposure

SNX-5422-CLN1-001
Exposure was ≤ 20 to 59 days for most (64%) patients; mean exposure = 80.4 days (range: 1-598 days). Last treatment cycle for most (72%) patients was Cycle 1, 2, or 3; mean = 3.4 cycles (range: 1-22 cycles).

SNX-5422-CLN1-004
Exposure was 40 to 59 days for most (67%) patients; median = 21 days (range: 3-23 days). Last treatment cycle for most (67%) patients was Cycle 2.

Table 3. Summary of Adverse Events

Adverse Event (AE)	Number of Patients (%)
	N=56
At least one treatment-emergent AE	56 (100%)
Treatment-related AE	53 (95%)
Grade 3 or 4 treatment-emergent AE	25 (45%)
Grade 5 AE (death)*	4 (7%)
Serious AE (SAE)	17 (30%)
Treatment-related SAE	3 (5%)
AEs leading to study discontinuation	13 (23%)
AEs leading to dose interruption	16 (29%)
Dose limiting toxicity	7 (13%)

* These included septic shock, cardio respiratory arrest, multi organ failure (none related), and treatment-related intestinal perforation.

Table 4. Most Frequent Treatment-Related Adverse Events* by Dose Schedule and Grade

Adverse Event	QOD schedule (n=36; 4-133 mg/m ²)		QD schedule (n=17; 50-89 mg/m ²)		Total (N=56)	
	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
	Number of Patients		Number of Patients		Number of Patients	
Diarrhea	17	2	11	4	30	6
Nausea	15	0	5	0	22	0
Fatigue	9	0	7	0	16	0
Vomiting	9	0	5	0	16	0
Abdominal pain	4	0	4	0	8	0
Anorexia	5	0	3	0	8	0
Dry mouth	2	0	3	0	5	0
Anemia	2	1	0	1	3	2

QOD=every other day; QD=once daily.
 * Reported by ≥10% of patients overall.
 †Includes 3 patients from the 50 mg/m² QD continuous dosing cohort.
 ‡ QD dosing regimen was associated with higher incidences of treatment-related AEs, with 20 patients experiencing 168 AEs vs. 36 patients experiencing 141 AEs on the QOD schedule.

Dose Limiting Toxicities (DLTs)

- 7 patients had DLTs, all Grade 3; most common DLT was diarrhea, with 6 incidences; there was 1 Grade 3 nictalopia (visual darkening). DLTs in 2 patients were SAEs (1 diarrhea and 1 GI hemorrhage).
- Events resolved in all patients, except 1 patient with Grade 2 dehydration.

Visual Adverse Events

- 4 patients had treatment-related nictalopia (visual darkening) and 1 had treatment-related blurry vision; all events were reversible, with complete recovery within a few days to a week following treatment discontinuation.
 - Nictalopia (visual darkening): 4 patients, Grade 1 to 3, with QD doses of 50 to 89 mg/m²; led to treatment discontinuation in 2 patients (1 on 89 mg/m² QD and 1 on 50 mg/m² QD continuous, who also had photophobia).
 - Blurry vision (Grade 1): 1 patient on 100 mg/m² QOD, retrospectively reported after dark adaptometry, showed an elevated threshold from Screening.


PHARMACOKINETICS

Table 5. Mean (±SD) SNX-2112 Pharmacokinetic Parameters for Day 21 (SNX-5422-CLN1-001 & 004)

Evaluable for PK	Dose (mg/m ²)	T _{max} (hr)*	C _{max} (ng/mL)	T _{1/2} (hr)	AUC ₀₋₂₄ (hr•ng/mL)
QOD Cohorts					
N=2	4	0.9 (0.7-1.0)	31 ± 15	9.9 ± 0.7	193 ± 40
N=3	5.32	2.0 (2.0-3.0)	42 ± 18	9.2 ± 0.8	451 ± 224
N=3	10.64	1.0 (0.7-1.0)	219 ± 219	12.4 ± 6.1	2410 ± 2770
N=3	21.28	3.0 (0.7-6.0)	460 ± 143	16.8 ± 3.6	6610 ± 4000
N=3	42	3.1 (1.0-6.0)	464 ± 272	15.1 ± 7.8	5340 ± 3550
N=3	56	2.0 (1.6-3.0)	770 ± 333	10.9 ± 1.3	6010 ± 3740
N=11	100	2.0 (0.8-4.0)	1220 ± 707	10.2 ± 2.1	10500 ± 8410
N=0	133	NR	NR	NR	NR
QD Cohorts					
N=6	50	1.6 (1.0-3.0)	579 ± 259	11.1 ± 1.6	3950 ± 1960
N=4	67	2.6 (1.0-4.0)	723 ± 233	9.8 ± 1.7	5770 ± 2120
N=1	89	NR	NR	NR	NR

T_{max}=time to maximum plasma concentration; C_{max}=maximum plasma concentration; AUC=area under the plasma concentration-time curve; QD=once daily; QOD=once every other day; SD=standard deviation; NR=not reported. Median and (range) reported for T_{max}.

Figure 1. Mean SNX-2112 Plasma Concentration-time Profiles on Day 1 and Day 21 of Treatment Cycle 1 for 100 mg/m² QOD



Pharmacokinetic Conclusions

- SNX-5422 (prodrug) rapidly converted to its active metabolite, SNX-2112. As expected, most samples collected post-dose showed no measurable concentrations of SNX-5422. Concentrations of SNX-2112 were detected as early as 0.33 hours after dosing.
- Peak concentrations of SNX-2112 following QOD and QD dosing were generally observed between 0.7 and 3.0 hours after dosing for both Day 1 and Day 21.
- SNX-2112 exhibited a relatively short terminal half-life (T_{1/2}) in plasma. T_{1/2} was similar across all cohorts in both studies, indicating that T_{1/2} appears independent of dose and dosing regimen. Overall, mean T_{1/2} in both studies ranged from 8.5 to 15.6 hours on Day 1 and from 9.2 to 16.8 hours on Day 21.
- SNX-5422 at QOD doses ranging from 4 to 100 mg/m² and QD doses ranging from 50 to 89 mg/m² produced dose-related increases in SNX-2112 exposures. C_{max} and AUC₀₋₂₄ generally increased in a linear manner with increasing dose; however, increases were greater than dose proportional.
- Comparison of SNX-2112 exposures on Day 1 and Day 21 showed minimal to no accumulation of SNX-2112 in plasma following either QOD or QD dosing for 21 days. There was no evidence of accumulation of SNX-2112 at the MTD of 100 mg/m² QOD.



EFFICACY

Antitumor Activity

- Antitumor activity was assessed in 43 patients (as 13 patients had no post-baseline tumor assessment data).
- Objective responses were observed (all on a QOD schedule) in:
 - 1 patient with prostate cancer (durable, complete response on 56 mg/m² QOD - see Case History).
 - 1 patient with adrenal cancer (unconfirmed partial response for 2 cycles on 5.32 mg/m² QOD).
 - 1 subject with breast cancer (partial response for 8 cycles on 56 mg/m² QOD).
- Stable disease was observed in 12 of 32 patients (38%) on a QOD schedule and in 7 of 11 patients (64%) on a QD schedule.
- Noteworthy stable disease was observed in:
 - 2 patients with neuroendocrine cancer (1 with liver/lung lesions on 100 mg/m² QOD and 1 with pancreatic lesions on 42 mg/m² QOD); both received 8 cycles before withdrawing from the study with stable disease.
 - 1 patient with hepatocellular cancer (on 42 mg/m² QOD) who received 6 cycles before withdrawing from the study.
 - 4 patients with stable disease for more than 4 cycles: 2 with prostate cancer (on 42 mg/m² QOD, and on 67 mg/m² QD), 1 with GIST (on 56 mg/m² QOD), and 1 with carcinoid of the small bowel (on 50 mg/m² QD).

Case History

- 69-year old Caucasian male, diagnosed with prostate cancer in June 1998.
- Progressive disease after 4 regimens of systemic anti-cancer therapy, ending June 2008.
- Started SNX-5422 56 mg/m² QOD in July 2008.
- 100% reduction of all target lesions (lymph nodes) reached in Cycle 8; prostate-specific antigen level = 0 ng/mL.
- Subject withdrew in Cycle 22 with complete response (100% reduction) in March 2010.
- Treatment was well-tolerated, with manageable diarrhea throughout treatment, and gastroesophageal reflux disease and duodenitis beginning at 1 year of treatment; all events were Grade 1.



CONCLUSIONS

- The MTDs were established at 67 mg/m² for QD, and 100 mg/m² for QOD.
- SNX-5422 monotherapy was generally well-tolerated at doses up to 67 mg/m² QD and 100 mg/m² QOD.
- Diarrhea was the most common AE and most common DLT event, but caused study discontinuation in only 2 patients (1 on 89 mg/m² QD and 1 on 133 mg/m² QOD). There were 8 incidences of dose interruption in 6 patients due to diarrhea.
- Treatment-related ocular toxicity appears to be schedule dependent and reversible, and was primarily observed with QD dosing [4 cases of nictalopia (visual darkening) at 50–89 mg/m² QD]. Nictalopia was not seen with QOD dosing. There was 1 case of blurry vision (Grade 1) that was retrospectively reported after dark adaptometry examination in a patient on QOD dosing.
- SNX-5422 monotherapy showed promising signs of clinical activity in patients with refractory solid tumors.
- Based on the superior benefit-risk profile of QOD dosing over QD dosing as observed in present preliminary clinical findings, 100 mg/m² QOD has been selected for further clinical testing.

References

- Neckers L, Workman P. *Clin Cancer Res.* 2012;18:64-76.
- Rajan A, et al. *Clin Cancer Res.* 2011;17:6831-9.
- Rice JW, et al. *Oncol Res.* 2009;18:229-42.
- Okawa Y, et al. *Blood.* 2009;113:846-55.
- Chandraratnam S, et al. *Clin Cancer Res.* 2008;14:240-8.

Acknowledgements

The authors would like to thank the study participants and their families as well as the study investigators and study team members. Content development support provided by Lorraine R. Baer, PharmD, Baer Pharm/med Consulting, Ltd.

Funding

These studies were sponsored by Serenex Inc./Pfizer Inc. and Esanex Inc.